Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of...
Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of tivantinib in patients with refractory or relapsed colorectal cancer, Burrill Institutional Research thinks its use in treating hepatocellular carcinoma (HCC) could still drive shares higher. In patients with HCC, Tivantinib demonstrated statistically significant results versus a placebo in reducing tumor progression, and the firm thinks the treatment could reach global peak sales of $278M.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs